Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NantKwest (NK) Competitors

NantKwest logo

NK vs. PRME, IKT, PLX, ZIVO, IZTC, CVM, CRTX, JATT, FNCH, and ALVR

Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), CEL-SCI (CVM), Cortexyme (CRTX), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), and AlloVir (ALVR). These companies are all part of the "medical" sector.

NantKwest vs. Its Competitors

Prime Medicine (NYSE:PRME) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Prime Medicine has a net margin of 0.00% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime MedicineN/A -107.87% -74.97%
NantKwest -76,658.58%-56.06%-46.93%

Prime Medicine has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500.

In the previous week, Prime Medicine had 8 more articles in the media than NantKwest. MarketBeat recorded 8 mentions for Prime Medicine and 0 mentions for NantKwest. Prime Medicine's average media sentiment score of 0.25 beat NantKwest's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Prime Medicine Neutral
NantKwest Neutral

Prime Medicine presently has a consensus target price of $8.92, indicating a potential upside of 148.03%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than NantKwest.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
NantKwest
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NantKwest has lower revenue, but higher earnings than Prime Medicine. NantKwest is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.96M97.52-$198.13M-$1.56-2.30
NantKwest$40K6,123.32-$65.79M-$0.70-3.20

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Prime Medicine beats NantKwest on 10 of the 17 factors compared between the two stocks.

Get NantKwest News Delivered to You Automatically

Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NK vs. The Competition

MetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$244.93M$283.04M$5.82B$9.75B
Dividend YieldN/AN/A3.84%4.09%
P/E Ratio-3.15N/A31.1425.96
Price / Sales6,123.32480.00475.48122.90
Price / CashN/A22.4437.1558.38
Price / Book1.8210.559.116.38
Net Income-$65.79M-$115.81M$3.26B$265.56M

NantKwest Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NK
NantKwest
N/A$2.24
-0.9%
N/A-48.6%$244.93M$40K-3.15160High Trading Volume
PRME
Prime Medicine
2.8974 of 5 stars
$3.24
-7.4%
$8.92
+175.2%
-26.8%$436.02M$4.96M-1.58234Gap Up
IKT
Inhibikase Therapeutics
1.7399 of 5 stars
$1.70
-1.2%
$6.50
+282.4%
+15.9%$126.38MN/A-0.646
PLX
Protalix BioTherapeutics
3.0621 of 5 stars
$1.53
-0.6%
$15.00
+880.4%
+62.9%$121.80M$61.95M-11.77200News Coverage
Analyst Revision
ZIVO
ZIVO Bioscience
0.2804 of 5 stars
$18.04
-2.4%
N/A+102.4%$68.86M$15.85K-3.7010News Coverage
Gap Up
IZTC
Invizyne Technologies
N/A$9.76
+0.6%
N/AN/A$61.02MN/A0.0029News Coverage
CVM
CEL-SCI
1.438 of 5 stars
$8.47
-5.0%
N/A-73.1%$58.29MN/A-17.6543
CRTX
Cortexyme
N/A$1.67
-1.2%
N/A+154.7%$50.35MN/A-0.5655
JATT
JATT Acquisition
N/A$1.74
+4.8%
N/A-50.7%$30.02MN/A0.003Gap Up
High Trading Volume
FNCH
Finch Therapeutics Group
N/A$12.50
-1.6%
N/A+22.1%$20.08MN/A-1.42190High Trading Volume
ALVR
AlloVir
N/A$2.50
+1.6%
N/A-85.5%$12.61MN/A-0.12110High Trading Volume

Related Companies and Tools


This page (NASDAQ:NK) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners